ISSN 1662-4009 (online)

ey0019.7-6 | Clinical Guidance | ESPEYB19

7.6. Gonadotropin-releasing hormone analogs for treatment of central precocious puberty in children less than 2 years of age

A Gohil , EA Eugster

J Pediatr. 2021 Dec 20:S0022-3476(21)01236-1. doi: 10.1016/j.jpeds.2021.12.030. PMID: 34942182https://www.sciencedirect.com/science/article/pii/S0022347621012361Brief Summary: This study evaluates the efficacy and safety of GnRH analogue treatment with Central Precocious Puberty (CPP) for patients under 2 y...

ey0021.10-10 | New Insights | ESPEYB21

10.10. SARS-CoV-2 infection and development of islet autoimmunity in early childhood

M Lugar , A Eugster , P Achenbach , Berge T von dem , R Berner , REJ Besser , al. et

Brief Summary: This longitudinal cohort study of 885 infants with high genetic risk of type 1 diabetes (T1D) explored the temporal association between SARS-CoV-2 infection and development of T1D–associated autoimmunity. The incidence rate of islet autoantibodies was higher in children with vs. without SARS-CoV-2 antibodies (7.8 vs. 3.5 per 100 person-years). Hence, SARS-CoV-2 infection appears temporally associated with the development of islet autoantibodies.<p class...

ey0018.7-3 | Clinical Guidance | ESPEYB18

7.3. Phase 3 trial of a small-volume subcutaneous 6-month duration leuprolide acetate treatment for central precocious puberty

KO Klein , A Freire , MG Gryngarten , GB Kletter , M Benson , BS Miller , TS Dajani , EA Eugster , N Mauras

J Clin Endocrinol Metab. 2020 Oct 1;105(10):e3660–71. 10.1210/clinem/dgaa479. https://academic.oup.com/jcem/article/105/10/e3660/5879679In brief: This phase 3 multi-centre, open-label, single-arm study explores the efficacy, pharmacokinetics and safety of 6-monthly 45-mg subcutaneous leuprolide acetate in 59 pati...